H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Monday, setting a price target of $210, which is approximately 208.42% above the present share price of $68.09.
Selvaraju expects Axsome Therapeutics Inc to post earnings per share (EPS) of -$0.61 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Axsome Therapeutics, with an average price target of $144.2.
The analysts price targets range from a high of $210 to a low of $101.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$21.13 million. The company's market cap is $2.54 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 33.2% and a 70.51% success rate.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.